Clinical Trials · NCT00068042

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

Name: A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Octreotide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Pfizer
Enrollment: 100
Start date: Apr 2003
Locations: 55 sites, 13 countries
Primary endpoint: Percentage of patients with normal IGF-1 concentration at Final Visit (Week 52)

View Octreotide compound reference